These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 35898553)

  • 21. Pharmacokinetic/Pharmacodynamic Evaluation of a Novel Aminomethylcycline Antibiotic, KBP-7072, in the Neutropenic Murine Pneumonia Model against Staphylococcus aureus and Streptococcus pneumoniae.
    Lepak AJ; Zhao M; Liu Q; Wang P; Wang Y; Bader JC; Ambrose PG; Andes DR
    Antimicrob Agents Chemother; 2019 Mar; 63(3):. PubMed ID: 30559140
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In Vivo Pharmacodynamics of Cefquinome in a Neutropenic Mouse Thigh Model of Streptococcus suis Serotype 2 at Varied Initial Inoculum Sizes.
    Guo C; Liao X; Wang M; Wang F; Yan C; Xiao X; Sun J; Liu Y
    Antimicrob Agents Chemother; 2016 Feb; 60(2):1114-20. PubMed ID: 26666923
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The integrated use of pharmacokinetic and pharmacodynamic models for the definition of breakpoints.
    Stass H; Dalhoff A
    Infection; 2005 Dec; 33 Suppl 2():29-35. PubMed ID: 16518709
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vivo pharmacokinetics and pharmacodynamics of the lantibiotic NAI-107 in a neutropenic murine thigh infection model.
    Lepak AJ; Marchillo K; Craig WA; Andes DR
    Antimicrob Agents Chemother; 2015 Feb; 59(2):1258-64. PubMed ID: 25512404
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preparation of Aditoprim Injection against
    Qu W; Dong M; Pan Y; Xie S; Yuan Z; Huang L
    Pharmaceutics; 2022 Mar; 14(4):. PubMed ID: 35456564
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics and Pharmacodynamics of Nemonoxacin in a Neutropenic Murine Lung Infection Model Against
    Li X; Chen Y; Xu X; Li Y; Fan Y; Liu X; Bian X; Wu H; Zhao X; Feng M; Guo B; Zhang J
    Front Pharmacol; 2021; 12():658558. PubMed ID: 34017256
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Population pharmacokinetic and pharmacodynamic modeling of high-dose intermittent ticarcillin-clavulanate administration in pediatric cystic fibrosis patients.
    Zobell JT; Stockmann C; Young DC; Cash J; McDowell BJ; Korgenski K; Sherwin CM; Spigarelli M; Chatfield BA; Ampofo K
    Clin Ther; 2011 Nov; 33(11):1844-50. PubMed ID: 22018680
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetic-Pharmacodynamic Evaluation of Gepotidacin against Gram-Positive Organisms Using Data from Murine Infection Models.
    Bulik CC; Okusanya ÓO; Lakota EA; Forrest A; Bhavnani SM; Hoover JL; Andes DR; Ambrose PG
    Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27872075
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetics and Pharmacodynamics of Tildipirosin Against
    Zeng D; Sun M; Lin Z; Li M; Gehring R; Zeng Z
    Front Microbiol; 2018; 9():1038. PubMed ID: 29867911
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Model-Informed Drug Development, Pharmacokinetic/Pharmacodynamic Cutoff Value Determination, and Antibacterial Efficacy of Benapenem against
    Ji XW; Xue F; Kang ZS; Zhong W; Kuan IH; Yang XP; Zhu X; Li Y; Lv Y
    Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31844001
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetic/Pharmacodynamic Correlation of Cefquinome Against Experimental Catheter-Associated Biofilm Infection Due to Staphylococcus aureus.
    Zhou YF; Shi W; Yu Y; Tao MT; Xiong YQ; Sun J; Liu YH
    Front Microbiol; 2015; 6():1513. PubMed ID: 26779167
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Toward Harmonization of Voriconazole CLSI and EUCAST Breakpoints for Candida albicans Using a Validated
    Beredaki MI; Georgiou PC; Siopi M; Kanioura L; Andes D; Arendrup MC; Mouton JW; Meletiadis J
    Antimicrob Agents Chemother; 2020 May; 64(6):. PubMed ID: 32229492
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics of gamithromycin in cattle with comparison of plasma and lung tissue concentrations and plasma antibacterial activity.
    Huang RA; Letendre LT; Banav N; Fischer J; Somerville B
    J Vet Pharmacol Ther; 2010 Jun; 33(3):227-37. PubMed ID: 20557439
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetic-pharmacodynamic integration and modelling of oxytetracycline administered alone and in combination with carprofen in calves.
    Brentnall C; Cheng Z; McKellar QA; Lees P
    Res Vet Sci; 2013 Jun; 94(3):687-94. PubMed ID: 23415880
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recommendations of Gentamicin Dose Based on Different Pharmacokinetic/Pharmacodynamic Targets for Intensive Care Adult Patients: A Redefining Approach.
    Abbasi MY; Chaijamorn W; Wiwattanawongsa K; Charoensareerat T; Doungngern T
    Clin Pharmacol; 2023; 15():67-76. PubMed ID: 37427084
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vivo pharmacodynamic characterization of a novel plectasin antibiotic, NZ2114, in a murine infection model.
    Andes D; Craig W; Nielsen LA; Kristensen HH
    Antimicrob Agents Chemother; 2009 Jul; 53(7):3003-9. PubMed ID: 19414576
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In Vivo Pharmacodynamic Target Investigation of Two Bacterial Topoisomerase Inhibitors, ACT-387042 and ACT-292706, in the Neutropenic Murine Thigh Model against Streptococcus pneumoniae and Staphylococcus aureus.
    Lepak AJ; Seiler P; Surivet JP; Ritz D; Kohl C; Andes DR
    Antimicrob Agents Chemother; 2016 Jun; 60(6):3626-32. PubMed ID: 27044547
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetic-pharmacodynamic cutoff values for benzylpenicillin in horses to support the establishment of clinical breakpoints for benzylpenicillin antimicrobial susceptibility testing in horses.
    Lallemand EA; Bousquet-Mélou A; Chapuis L; Davis J; Ferran AA; Kukanich B; Kuroda T; Lacroix MZ; Minamijima Y; Olsén L; Pelligand L; Portugal FR; Roques BB; Santschi EM; Wilson KE; Toutain PL
    Front Microbiol; 2023; 14():1282949. PubMed ID: 37954237
    [TBL] [Abstract][Full Text] [Related]  

  • 39.
    Guo LL; Gao RY; Wang LH; Lin SJ; Fang BH; Zhao YD
    Front Vet Sci; 2021; 8():715887. PubMed ID: 34869712
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Concentration-Dependent Activity of Pazufloxacin against
    Umezaki Y; Matsumoto K; Ikawa K; Yokoyama Y; Enoki Y; Shigemi A; Watanabe E; Nakamura K; Ueno K; Terazono H; Morikawa N; Takeda Y
    Antibiotics (Basel); 2022 Jul; 11(7):. PubMed ID: 35884236
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.